2026-01-12 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

### Company Overview
Johnson & Johnson is a multinational healthcare company that develops and manufactures medical devices, pharmaceuticals, and consumer packaged goods.

### Compare with S&P 500 (VOO)

| Metric | JNJ (review) | VOO (comparison) | Divergence |
|------|-------------|------------------|------------|
| Cumulative Return | 50.20% | 94.03% | -43.80 |
| Return Rate (rate) | N/A | N/A | N/A |
| Return Rate (rate_vs) | N/A | N/A | N/A |

### Alpha, Beta Analysis

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|----|------|------|-------|------|-------|
| 2016-2018 | 6.0% | 16.8% | 3.0% | 0.7 | 310.9B |
| 2017-2019 | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020 | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021 | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022 | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023 | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024 | -30.0% | 13.8% | -50.0% | 0.2 | 348.4B |
| 2023-2025 | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

### Recent Stock Price Fluctuations

* 5-day SMA: $205.35
* 20-day SMA: $207.70
* 60-day SMA: $199.99
* Close: $204.39
* Last-market: -$0.66 (sharp decline)

### RSI, PPO Index Indicators

* RSI: 38.51
* PPO: -0.36
* Expected Return: -74.90%
* Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: -6.80 (worsening)

### Recent News & Significant Events

* Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
* CX Institutional Purchases 5,165 Shares of Johnson & Johnson $JNJ - MarketBeat
* More Upside For JNJ Stock In 2026? - Forbes
* Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday - TechStockÂ²
* Has Johnson & Johnson (JNJ) Run Too Far After Its 44.3% One-Year Surge? - simplywall.st
* Millions to get cheaper medicines as J&J builds new drug plants in U.S. - Stock Titan

### Analyst Opinions

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 212.00 / 240.00 / 155.00

### Recent Earnings Analysis

| Date | EPS | Revenue |
|-----|----|---------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3 | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-10-22 | 1.12 | 22.47 B$ |

### Financial Information

#### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

#### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

### Comprehensive Analysis (Summary of previous items)

* Johnson & Johnson's stock price has fluctuated, with a sharp decline lately.
* The cumulative return of JNJ is lower than the S&P 500, indicating a divergence of -43.80.
* The RSI and PPO indicators suggest a mixed signal, with a bearish trend.
* Analyst consensus recommends buying JNJ stock, with a target price range of $212.00 to $240.00.
* The recent earnings analysis shows a mixed trend, with revenue increasing but EPS fluctuating.
* Financial information suggests a stable profitability and ROE, but a downward trend in equity.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.